The Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S) initiative was launched in an effort to address specific gaps in the understanding of the psychosocial impact of mild-moderate-severe hemophilia B. The original Hemophilia Experiences, Results and Opportunities (HERO) qualitative study evaluated the needs of people with hemophilia A or B in multiple countries; however, a majority of participants had the more common moderate-severe hemophilia A. The B-HERO-S study was designed in collaboration with the hemophilia community to evaluate the needs of adults with hemophilia B and caregivers of children with hemophilia B, including affected women and caregivers of girls with hemophilia. The report presented here describes participant demographics and comorbidities, as well as treatment regimens and access to treatment. Bleeding symptoms were reported by 27% of mothers of children with hemophilia B who participated. Women were more likely than men to self-report arthritis and depression/anxiety as comorbidities associated with hemophilia B. More adults and children with hemophilia B were on routine treatment than on on-demand treatment, and a high percentage of adults with moderate hemophilia B received routine treatment (86%). Many adults with hemophilia B (78%) and caregivers (69%) expressed concern about access to factor in the next 5 years, and of adults with hemophilia B, women more commonly experienced issues with access to factor in the past than did men (72% vs 44%). The findings of the B-HERO-S study reveal potential unmet needs of some patients with mild-moderate hemophilia B, and the results may be leveraged to inform patient outreach by hemophilia treatment centers and education initiatives.
| INTRODUCTION
Hemophilia is a bleeding disorder characterized by a deficiency in coagulation factor VIII (hemophilia A) or factor IX (FIX) (hemophilia B). 1 Individuals with hemophilia experience bleeding symptoms, often including recurrent bleeding into joints (hemarthrosis), which over time may result in pain and joint damage. 1, 2 Pain and arthropathy associated with hemophilia can affect physical function and quality of life. 3, 4 Obtaining a deeper understanding of the impact of hemophilia on affected individuals and their families is critical in informing approaches toward improving comprehensive care.
Previous studies have qualitatively assessed the psychosocial issues confronted by people with hemophilia, typically through questionnaires or in-person interviews. However, the methodology, instruments used, and participant types in these studies are heterogeneous, making it difficult to compare results among them. 5 The
Hemophilia Experiences, Results and Opportunities (HERO) initiative was designed to address the need for a broad assessment of the psychosocial issues faced by people with hemophilia and those who care for them through literature reviews, qualitative interviews, and a quantitative study. The quantitative study assessed issues such as quality of life, relationships, and treatment characteristics of 675 people with hemophilia and 561 parents of children with hemophilia in 10 different countries, including 189 patients and 190 parents in the United States. [6] [7] [8] The results of HERO demonstrated that increased disability and pain were correlated with lower quality of life and lower employment rates 7 and that globally 41% of people with hemophilia and 30% of parents of children with hemophilia reported difficulty with access to treatment. 8 In addition, approximately onethird of people with hemophilia who participated in HERO believed that hemophilia had a negative impact on their ability to form close relationships. 8 While HERO was unprecedented in depth and scope, HERO participants were mostly males affected with hemophilia A of moderatesevere severity (74% of people with hemophilia, 75% of children described by participating parents). Therefore, the HERO results may not accurately reflect the experiences of individuals with hemophilia B, and particularly those with mild-moderate disease. In addition, no study has comprehensively evaluated the psychosocial impact of FIX deficiency on women and girls. Although these individuals are typically classified as carriers, in some cases, the loss of one functional copy of the gene that encodes for factor VIII or FIX through lyonization is sufficient to lead to deficiency and/or cause bleeding symptoms. 9 Hence, there is a need to assess the impact of FIX deficiency on various aspects of the lives of people with hemophilia B across all severities, including women and girls.
In cooperation with the hemophilia community (healthcare professionals, advocacy organizations, patients, and caregivers) in the United States, the Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions, or B-HERO-S, pilot study was developed to evaluate the needs of adults and children affected by hemophilia B. B-HERO-S was designed to describe the psychosocial impact of the disease, as well as to identify unmet needs in this specific population. Information regarding disability benefits and household income of study participants was collected, providing a more comprehensive view of the impact on the families of individuals with hemophilia B. Furthermore, the survey included questions that were specific to female respondents, allowing for the opportunity to explore the impact of hemophilia B on affected women and girls. In addition, treatment regimens and types of products used for treatment were assessed, and caregivers were asked to describe the impact of caring for a child with hemophilia B on their spouse/ partner.
The aim of this manuscript is to describe in detail the methods used in the B-HERO-S study, as well as the demographics and treatment patterns of participants. Parallel manuscripts in this supplement describe other areas of investigation from the study, including participation in recreational activities and alterations to treatment regimens to accommodate physical activity, and the impact of hemophilia B on education and work life of people with hemophilia B and caregivers of children with hemophilia B.
| PATIENTS AND METHODS

| Study design and participant recruitment
B-HERO-S was an online cross-sectional study conducted within the Board (IRB) (Quorum Review IRB, Seattle, WA, USA), including an informational letter that was provided to the advocacy organizations for distribution/posting. Informed consent was formally waived for the study due to minimal risk criteria based upon IRB review and approval.
There were no assessments for safety and effectiveness in this noninterventional, one-time, cross-sectional study as no products were involved.
| Survey assessments
This study used two distinct questionnaires, one for adults with hemophilia B (aged ≥18 years) and one for caregivers, including
non-parents, reporting on behalf of their oldest child with hemophilia B (aged <18 years). The surveys each contained approximately 100 questions and required approximately 45-60 minutes to complete. Questions assessed participant demographics and patients' hemophilia characteristics and management strategies.
Patient-centric terminology was used to best understand adult and caregiver experiences, particularly around bleeding and treatment (eg, "routine treatments" to prevent bleeding with various frequencies instead of grouping into "prophylaxis," extra doses around activity instead of "situational prophylaxis"), with examples provided to illustrate (eg, traumatic bleeds as relating to "a fall or being hit," a significant change to treatment around activity being "switch to routine treatments to prevent bleeding"). Survey instruments also assessed frequency and intensity of participation in physical activities, comorbidities, and the impact of hemophilia on daily activities, education/employment, and family and personal Analysis of reliability and validity of these PROs will be reported separately. All question stems were closed-ended, and while some questions allowed for a null response (eg, "Don't know") or alternative (eg, "Other"), there were no free text fields. An additional supplemental question prompting for FIX activity level was posed to adult participants to obtain an independent assessment of hemophilia severity. The objective was to insure that female participants responding as adult patients had FIX levels <50% and were distinguished from female participants responding instead to the caregiver survey (including "symptomatic carriers"). hemophilia was 6.5 (0-46) years. While median age of diagnosis was similar between men (7 years) and women (6 years), the median age of diagnosis for those with mild hemophilia was 14 years compared with 6 years for those with moderate hemophilia and <1 year for severe disease.
| RESULTS
| Demographics and participant characteristics
Most adults reported having moderate hemophilia (63%); few (1%) reported having hemophilia with inhibitors (Table 1) . Self-reported hemophilia severity based on question stems showing standardized diagnostic FIX levels (eg, severe <1%) among adults with hemophilia was not always concordant with the supplemental responses for self-reported FIX levels ( Table 2) . Of the adults with hemophilia who reported their factor levels, most with mild or moderate hemophilia reported FIX levels within the range corresponding to their disease severity; many with severe hemophilia, however, reported FIX levels above the diagnostic range associated with severe hemophilia (consistent assessments for men/women: mild, 87%/72%; moderate, 90%/91%; severe, 65%/20%). Factor level data were not further classified as being baseline levels or levels on replacement therapy.
Of the caregivers who participated in the study, 116 (77%) were mothers and 34 (23%) were fathers; no respondents were non-parent caregivers. Ninety-three percent of caregivers had one child with hemophilia and 7% had two children with hemophilia. A majority of caregivers (81%) had at least one son with hemophilia, while 21% had one daughter with mild-moderate-severe hemophilia (none had more than one daughter with hemophilia).
| Household income and disability benefits
Among adults with hemophilia B, 45% reported receiving disability benefits, including 20% of those with mild hemophilia, 56% of those with moderate hemophilia, and 38% of those with severe hemophilia (Table 3) . Disability benefits were more common among those who were married or in a long-term relationship (63%), those who were receiving some form of routine infusions (52%), and women (57%).
Adults with hemophilia B aged <30 years/30-45 years more commonly received disability benefits (41%/53%) compared with those aged >45 years (33%). A similar percentage of women (33%) and men (29%) reported a household income ≥$100,000. Overall, 30% of adults with hemophilia B had an annual household income ≥$100,000;
however, only 12% of those with severe hemophilia reported a household income ≥$100,000.
Overall, 39% of families with children with hemophilia B reported receiving disability benefits for their child. A higher percentage of those with children with moderate hemophilia (55%) received benefits, compared with those with mild (19%) or severe (12%) hemophilia.
Fifty-five percent of children with hemophilia who were receiving some form of routine infusions received disability benefits. More than half (56%) of caregivers reported a household income ≥$100,000, and 24% of caregivers had a household income within the $60,000-$99,000 range.
| Bleed history
Adults with hemophilia B reported a median (range) of four bleeds (0, 50) in the prior year that required treatment. Median number of bleeds varied across hemophilia severities (mild, 1; moderate, 4; severe, 4; inhibitors, 6). Adults who received "on-demand treatment for bleeding" and "routine treatment" in any of three prespecified frequencies per month had a median of five and four bleeds, respectively, in the past year; those with a mostly on-demand regimen for bleeds who reported supplementing with any additional doses (eg, around activity) had a median of five bleeds. Most bleeds occurred in joints (62%) compared with muscle (27%), mucosal (7%), or other locations (3%). A higher percentage of women responding as adult patients than men reported that their last bleed occurred in a joint (73% vs 57%), and a lower percentage reported that their last bleed occurred in a muscle (21% vs 30%). Overall, only 27% of adults with hemophilia B had a specific joint that was particularly affected by bleeds; this was higher for participants with severe hemophilia (64%) or hemophilia with inhibitors (67%), compared with those with mild (15%) or moderate (22%) hemophilia. More than half (60%) of adults with hemophilia B with a specific problem joint reported that the T A B L E 2 Self-reported hemophilia severity at diagnosis vs self-reported factor level (adults with hemophilia) knee joint suffered from bleeds most often. Of women respondents, only 1% reported mucosal and 3% reported "other" types of bleeding. Median perceived disease control on a scale of 1-10 (1=not at all well controlled, 10=extremely well controlled) was 7 and was similar across hemophilia severities (mild/moderate/severe, 7/7/8).
The most common cause of a bleeding episode in adults with hemophilia B was trauma (eg, a fall or being hit) (42%), and repetitive activity was reported to cause 26% of recent bleeds ( Figure 1A ). Work- specific joint bleeding. In reference to disease control, the median rating by caregivers on a scale of 1-10 (1=not at all well controlled, 
| Comorbidities of adults with hemophilia B
Arthritis was the most common self-reported comorbidity related to hemophilia in adults with hemophilia B, and was more prevalent in those with moderate (55%) or severe (59%) hemophilia than in those with mild hemophilia (26%) ( Table 4 ). Acute/intermittent pain was reported across all hemophilia severities and was more common than chronic/persistent pain (29% vs 13%). The prevalence of chronic pain increased with age; 40% of adults with hemophilia B aged >45 years reported chronic pain, compared with 12% of those aged ≤45 years.
Women with hemophilia B more frequently reported anxiety (43%) or depression (42%) compared with men (15% and 14%); anxiety/ depression were also more prevalent among respondents aged 30-45 years (34%/31%) compared with those aged <30 years (18%/17%) or >45 years (20%/20%). Overall, osteoporosis and bone fractures were reported by 43% and 11%, respectively; women reported osteoporosis (56%) more commonly than men; however, bone fractures were more frequently reported by men (13%) than by women (6%).
Only 9% of adults with hemophilia B reported having human immunodeficiency virus (HIV)/AIDS, and 5% reported having hepatitis C virus (HCV). More than half (54%) of HIV patients reported having received prior treatment for HIV, and 24% were currently receiving treatment.
Patients with HCV reported treatment as current (9%), prior (35%), complete with HCV removed (17%), or never (39%).
| Hemophilia treatment
Overall, the most common treatment used by adults with hemophilia B at any point in their life was recombinant FIX (63%), while 6% of adults with hemophilia B were treated with bypassing agents at some time ( Figure 3A ). Long-acting recombinant FIX was slightly more commonly used by those with moderate hemophilia (36%) compared with mild (20%) or severe (28%) hemophilia, and by those receiving some form of routine infusions (33%) compared with on-demand (29%) or mostly on-demand (15%) therapy.
When asked "who had the main responsibility for their hemophilia care," a majority of adults with hemophilia (55%) reported that their hematologist was responsible for their care compared with nurses (12%) or being responsible for their own care (27%); patients with severe hemophilia more commonly had the main responsibility for their care compared with those with mild/moderate hemophilia (69% vs 38%/16%). Treatment decisions were more often made in coordination with the physician or nurse at the hemophilia treatment center (HTC) than by the patients themselves (61% vs 16% regimens between women and men (Table 5 ). However, treatment regimens varied across hemophilia severities; routine infusions at various intervals to prevent bleeding were reported by 63%, 86%, and 81% of those with mild, moderate, and severe hemophilia, respectively. Of those receiving some form of routine infusions, the most common regimen was infusing ≥1 time per week (67%). Higher percentages of those with severe (72%) and moderate (71%) hemophilia reported receiving routine infusions for ≥25% of their lives, compared with 31% of those with mild hemophilia.
For children with hemophilia B, the most common therapies used were recombinant and plasma-derived FIX (55% and 40%, respectively) ( Figure 3B ). Fresh frozen plasma was used at some time for 42% of those children with severe hemophilia, while plasma-derived FIX was used at some time for 52% of those with moderate hemophilia. Overall, long-acting recombinant FIX was used by 17% of children with hemophilia B. A majority of children with hemophilia (65%) were receiving any of the prespecified categories of routine infusions; 23% reported infusions ≥1 time a week, 27% ≥1 time a week with extra infusions ahead of physical activity, and 15% ≥2 times a month (Table 5 ). When considering hemophilia severity and inhibitor status, only 25% of children with mild hemophilia received any frequency of routine infusions to prevent bleeding, whereas 70%/81% of children with moderate/severe hemophilia and 66% of children with inhibitors were receiving routine infusions. Overall, 39% of children with hemophilia B received routine infusions ≥50% of their lifetime, with 4% having always been on routine infusions. All children with severe hemophilia received treatment >25%
of their lives, compared with 25%/70% of children with mild/moderate hemophilia.
F I G U R E 3 Types of products used
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| Access to factor/treatment
In general, both adults with hemophilia B and caregivers expressed problems with access to factor over the past 5 years due to availability and/or affordability ( Figure 4A,B) . Furthermore, 78% of adults with hemophilia and 69% of caregivers expressed concern about the ability to obtain factor due to availability or affordability in the next 5 years.
Of adults with hemophilia B, women were more likely than men to have had issues with access to factor in the past 5 years (72% vs 44%).
Among those who reported difficulties in obtaining replacement factor products, adults with hemophilia/caregivers most commonly reported difficulties due to a lack of supply at their specialty pharmacy or home care (43%/39%) or throughout the country (35%/22%), because they could not personally afford treatment (31%/19%) or co-payments (18%/27%), or because of a change in HTC policy on prescriptions or refills (30%/25%). 
| Healthcare professional visits
Severe (n=33)
On-demand treatment of bleeding episodes 31 (10) 15 (20) 14 (7) 1 (3) 24 (11) 7 (8) 26 (17) 12 (44) 14 (17) 0 (0)
Routine infusions to prevent bleeding Two or more times per month 36 (12) 9 (12) 23 (12) 3 (9) 25 (12) 11 (13) 22 (15) 3 (11) 12 (14) 5 (15) One or more times per week 121 (40) 18 (24) 90 (48) 11 (34) 87 (41) 34 (40) 34 (23) 2 (7) 17 (20) 13 (39) One or more times per week with extra infusions ahead of moderate-vigorous activity 81 (27) 20 (27) 49 (26) 12 (38) 53 (25) 28 (33) 41 (27) 2 (7) 30 (36) 9 (27) Mostly on-demand treatment of bleeding With occasional infusions ahead of anticipated activities to avoid bleeding 21 (7) 7 (9) 10 (5) 4 (13) 18 (8) 3 (3) 22 (15) 7 (26) 9 (11) 5 (15) With occasional periods of prolonged treatment 5 (2) 2 (3) 3 (2) 0 (0) 4 (2) 1 (1) 5 (3) 1 (4) 2 (2) 1 (3) Don't know/decline to answer 4 (1)
3 (4) 0 (0) 1 (3) 2 (1) 2 (2) 0 (0)
Issues with access to factor due to availability or affordability or hemophilia nurse (25%); these values were higher for adults with severe hemophilia (56% and 47%). A minority of adults visited a physical therapist (28% overall; 23%/26%/50% for mild/moderate/severe), or a social worker (10% overall; 11%/5%/31% for mild/moderate/ severe). Those with severe hemophilia were more likely to have their care team include a social worker (42%) or a physical therapist (25%) compared with those with mild/moderate disease (17%/1% for social worker and 17%/13% for physical therapist). The most common mode of communication between adults with hemophilia and healthcare professionals was via clinic visits (78%).
Overall, caregivers reported that children with hemophilia B had a median of four HTC visits in the past year, although 13% reported they had not been to the HTC or clinic for management. Whereas children with moderate hemophilia had a median of three visits, those with mild or severe hemophilia had a median of five visits, and those with inhibitors had 12 visits. Ninety percent of caregivers said it was very or quite easy to access the HTC. The length of travel time (43%), cost of travel (43%), and distance (50%) were the most common reasons for difficulty in reaching the HTC. Infusions were often performed by the caregiver, a family member, or the child with hemophilia (73%), and less frequently were administered by a nurse at the HTC or at home (27%). Infusions were performed always at home or at the child's location (15%), mostly at home but sometimes at the HTC or hospital (32%), mostly at the HTC or hospital but sometimes at home (35%), or typically first dose at home and further doses if needed at the HTC or hospital (13%). Caregivers rarely reported that treatment administration occurred exclusively at the HTC or hospital (5%).
Most children with hemophilia B (81%) saw a hematologist for treatment or for complications related to hemophilia; many reported seeing a nurse (45%), nurse practitioner or physician assistant (45%), or physical therapist (42%) ( Figure 5B ). Generally, caregivers were very/quite satisfied with the care their child received from their healthcare professional (hematologist, 47%/52%; nurse practitioner or physician assistant, 52%/48%; nurse, 55%/43%; social worker, 52%/38%).
| DISCUSSION
The B-HERO-S study was designed as a pilot study to evaluate the impact of hemophilia B on adults with hemophilia, children with hemophilia, and their families, with a particular focus on individuals with mild-to-moderate disease and affected women and girls. B-HERO-S builds upon the recent HERO study and addresses specific follow-up questions raised by HERO, in addition to expanding enrollment to groups excluded from that study. People with hemophilia B made up only a small proportion of US respondents in HERO. 6 In addition, individuals with mild-to-moderate hemophilia may have been excluded from HERO, as inclusion criteria required that participants were either on regular factor replacement therapy or had a spontaneous bleed in the past 12 months. 6 Adult women with hemophilia and caregivers of 39/394, 10%) in the United States; women were overrepresented in the B-HERO-S study compared to the proportion of women included in the ATHN Dataset.
| CONCLUSIONS
The B-HERO-S initiative provided the opportunity to evaluate the psy- Going forward, the B-HERO-S pilot study framework could also be leveraged as a global platform to more broadly examine these issues across countries and healthcare systems.
